Peter Williams - Omeros Vice Resources
| OMER Stock | USD 11.35 0.56 4.70% |
Executive
Peter Williams is Vice Resources of Omeros
| Age | 56 |
| Address | The Omeros Building, Seattle, WA, United States, 98119 |
| Phone | 206 676 5000 |
| Web | https://www.omeros.com |
Peter Williams Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Williams against Omeros stock is an integral part of due diligence when investing in Omeros. Peter Williams insider activity provides valuable insight into whether Omeros is net buyers or sellers over its current business cycle. Note, Omeros insiders must abide by specific rules, including filing SEC forms every time they buy or sell Omeros'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Williams over three months ago Disposition of 3416 shares by Peter Williams of Fluence Energy at 17.01 subject to Rule 16b-3 |
Omeros Management Efficiency
The company has return on total asset (ROA) of (0.2687) % which means that it has lost $0.2687 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7633) %, meaning that it created substantial loss on money invested by shareholders. Omeros' management efficiency ratios could be used to measure how well Omeros manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/01/2024, Return On Equity is likely to grow to 4.95, while Return On Tangible Assets are likely to drop (0.33). At this time, Omeros' Intangibles To Total Assets are relatively stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Arthur Levin | Avidity Biosciences | 70 | |
| Erin Campany | Mirum Pharmaceuticals | 56 | |
| Stuart Henderson | Passage Bio | N/A | |
| Matthew JD | Enanta Pharmaceuticals | 51 | |
| Scott MD | Protagonist Therapeutics | N/A | |
| Patrick Lucy | Ligand Pharmaceuticals Incorpor | N/A | |
| Jayne Gershkowitz | Amicus Therapeutics | 67 | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Scott Gangloff | Akero Therapeutics | 50 | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Todd Edwards | Arcutis Biotherapeutics | 60 | |
| Juan MD | Biomea Fusion | N/A | |
| Matthew JD | Protagonist Therapeutics | 53 | |
| Marc CPA | Crinetics Pharmaceuticals | 45 | |
| JeanLuc Girardet | Mirum Pharmaceuticals | N/A | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| Carter King | Protagonist Therapeutics | 53 | |
| Joanne MD | Mirum Pharmaceuticals | 60 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -5.76 | ||||
| Return On Asset | -0.27 |
Omeros Leadership Team
Elected by the shareholders, the Omeros' board of directors comprises two types of representatives: Omeros inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Omeros. The board's role is to monitor Omeros' management team and ensure that shareholders' interests are well served. Omeros' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Omeros' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nadia Dac, VP Officer | ||
| Debra MT, Chief Officer | ||
| Andreas MD, Chief Officer | ||
| Gregory MD, Chairman, CoFounder | ||
| Catherine Melfi, Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer | ||
| Peter JD, General VP | ||
| Michael Jacobsen, Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Treasurer | ||
| Pamela MD, CoFounder | ||
| Peter Williams, Vice Resources | ||
| David Borges, Chief Finance | ||
| MD JD, VP Officer |
Omeros Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Omeros a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.76 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 744.04 M | ||||
| Shares Outstanding | 57.95 M | ||||
| Shares Owned By Insiders | 4.44 % | ||||
| Shares Owned By Institutions | 43.72 % | ||||
| Number Of Shares Shorted | 10.73 M | ||||
| Price To Earning | 0.73 X | ||||
| Price To Book | 8.44 X | ||||
| Price To Sales | 4.93 X |
Pair Trading with Omeros
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Omeros position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Omeros will appreciate offsetting losses from the drop in the long position's value.Moving together with Omeros Stock
Moving against Omeros Stock
| 0.67 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.63 | BCH | Banco De Chile | PairCorr |
| 0.54 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.49 | HLN | Haleon plc | PairCorr |
| 0.49 | ANRO | Alto Neuroscience, | PairCorr |
The ability to find closely correlated positions to Omeros could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Omeros when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Omeros - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Omeros to buy it.
The correlation of Omeros is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Omeros moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Omeros moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Omeros can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Omeros Stock Analysis
When running Omeros' price analysis, check to measure Omeros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omeros is operating at the current time. Most of Omeros' value examination focuses on studying past and present price action to predict the probability of Omeros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omeros' price. Additionally, you may evaluate how the addition of Omeros to your portfolios can decrease your overall portfolio volatility.